Cardiac Amyloidosis Clinical Trial
Official title:
Frontline Thalidomide for Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide
To prove the organ-reversing potential of thalidomide for amyloidosis with cardiac involvement
Considering that dismal prognosis of amyloidosis is attributable to organ dysfunction,
primary aim of amyloidosis treatment should be an organ reversal. However, due to various
reasons, not much is known about organ reversal in amyloidosis. Almost all of the clinical
trials evaluated hematologic response in amyloidosis. Meanwhile, besides autologous stem cell
transplantation with high-dose melphalan conditioning, hematologic response rate of various
agents such as bortezomib, melphalan, thalidomide and lenalidomide are similar for
amyloidosis. However, organ reversing potential of these agents is not known. If there is a
difference in organ reversing potential despite of similar hematologic response rate, drug
with effective organ reversing potential should be a standard treatment for amyloidosis.
The investigators assume that thalidomide could make organ reversal in cardiac amyloidosis
due to its specific mechanism of action. To prove this concept, the investigators propose a
clinical trial that evaluates organ reversing potential of thalidomide in cardiac
amyloidosis.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04459169 -
Cardiac Amyloidosis : Diagnostic Using Red Flag Signals
|
||
| Recruiting |
NCT03029026 -
The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
|
||
| Recruiting |
NCT06034405 -
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
|
||
| Recruiting |
NCT04915235 -
Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
|
||
| Terminated |
NCT03333551 -
Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy
|
Phase 4 | |
| Recruiting |
NCT04105634 -
Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT
|
Early Phase 1 | |
| Recruiting |
NCT05139797 -
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
|
||
| Not yet recruiting |
NCT05593679 -
A Multi-center Cardiac PYP Scan Registry in Taiwan.
|
||
| Not yet recruiting |
NCT04146415 -
Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera
|
N/A | |
| Recruiting |
NCT03626584 -
PET/MR Imaging In Patients With Cardiac Amyloidosis
|
||
| Recruiting |
NCT04856267 -
Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders
|
||
| Completed |
NCT03119558 -
PET/MRI Evaluation of Cardiac Amyloid
|
Early Phase 1 | |
| Recruiting |
NCT02798705 -
Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
|
||
| Not yet recruiting |
NCT04387344 -
Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis
|
||
| Recruiting |
NCT06129656 -
Cardiac Amyloidosis Registry of University Hospital Leipzig
|
||
| Terminated |
NCT01683825 -
Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
|
Phase 4 | |
| Withdrawn |
NCT04363294 -
Targeted Testing for ATTR Among Aortic Stenosis Patients-Pilot
|
N/A | |
| Not yet recruiting |
NCT04661800 -
Study of Olfactory Disorders in Patients With Cardiac Amyloidosis
|
N/A | |
| Terminated |
NCT03232632 -
Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.
|
Early Phase 1 | |
| Recruiting |
NCT04830696 -
3D ECG for Detection of Cardiomyopathy
|